(RDNT) RadNet - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 4.278m USD | Total Return: -4.5% in 12m
Avg Turnover: 40.1M
EPS Trend: -51.4%
Qual. Beats: -1
Rev. Trend: 99.7%
Qual. Beats: 8
Warnings
High Debt/EBITDA (7.2) with thin interest coverage (1.4)
High Debt while negative Cash Flow
Altman Z'' 0.20 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
RadNet, Inc. (RDNT) is a major provider of outpatient diagnostic imaging services, operating across two primary segments: Imaging Centers and Digital Health. The company offers a comprehensive range of modalities, including MRI, CT, PET, and mammography, while simultaneously developing proprietary software for image distribution and storage.
The outpatient imaging sector is characterized by a shift toward value-based care, as freestanding centers typically offer lower costs compared to hospital-based departments. RadNet integrates artificial intelligence into its workflow to enhance the interpretation of breast, lung, and prostate scans, aiming to improve diagnostic accuracy and operational efficiency.
The company’s Digital Health division focuses on cloud-native operating systems and informatics solutions designed specifically for the radiology environment. For a deeper look at industry valuation metrics, consider exploring the data available on ValueRay.
Founded in 1981 and headquartered in Los Angeles, RadNet maintains a significant footprint in the healthcare services industry by combining physical clinical operations with advanced health informatics.
- AI-powered diagnostic tools drive higher margin Digital Health segment revenue growth
- Aging population demographics increase demand for high-modality outpatient imaging services
- Private payer reimbursement rate adjustments impact core imaging center profitability
- Strategic joint ventures with health systems expand regional market share and utilization
- Radiologist labor shortages and wage inflation increase operational cost pressures
| Net Income: -14.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -6.16 > 1.0 |
| NWC/Revenue: 4.90% < 20% (prev 27.31%; Δ -22.40% < -1%) |
| CFO/TA 0.09 > 3% & CFO 349.6m > Net Income -14.2m |
| Net Debt (2.33b) to EBITDA (322.8m): 7.21 < 3 |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.1m) vs 12m ago 3.60% < -2% |
| Gross Margin: 9.38% > 18% (prev 0.12%; Δ 926.2% > 0.5%) |
| Asset Turnover: 59.39% > 50% (prev 56.03%; Δ 3.36% > 0%) |
| Interest Coverage Ratio: 1.44 > 6 (EBITDA TTM 322.8m / Interest Expense TTM 70.3m) |
| A: 0.03 (Total Current Assets 740.8m - Total Current Liabilities 635.6m) / Total Assets 3.89b |
| B: -0.03 (Retained Earnings -128.9m / Total Assets 3.89b) |
| C: 0.03 (EBIT TTM 101.3m / Avg Total Assets 3.61b) |
| D: -0.05 (Book Value of Equity -131.4m / Total Liabilities 2.53b) |
| Altman-Z'' = 0.20 = B |
| DSRI: 0.78 (Receivables 209.1m/235.0m, Revenue 2.14b/1.87b) |
| GMI: 1.27 (GM 9.38% / 11.92%) |
| AQI: -0.09 (AQ_t -0.03 / AQ_t-1 0.28) |
| SGI: 1.15 (Revenue 2.14b / 1.87b) |
| TATA: -0.09 (NI -14.2m - CFO 349.6m) / TA 3.89b) |
| Beneish M = -3.60 (Cap -4..+1) = AAA |
As of May 27, 2026, the stock is trading at USD 54.12 with a total of 529,271 shares traded.
Over the past week, the price has changed by -0.09%,
over one month by -6.29%,
over three months by -24.93% and
over the past year by -4.52%.
RadNet has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy RDNT.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 89.8 | 65.8% |
P/E Forward = 36.63
P/S = 1.9948
P/B = 3.9574
P/EG = 0.9574
Revenue TTM = 2.14b USD
EBIT TTM = 101.3m USD
EBITDA TTM = 322.8m USD
Long Term Debt = 1.06b USD (from longTermDebt, last quarter)
Short Term Debt = 93.1m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 847.9m
Net Debt = 2.33b USD (calculated: Debt 2.78b - CCE 455.3m)
Enterprise Value = 6.60b USD (4.28b + Debt 2.78b - CCE 455.3m)
Interest Coverage Ratio = 1.44 (Ebit TTM 101.3m / Interest Expense TTM 70.3m)
EV/FCF = -44.40x (Enterprise Value 6.60b / FCF TTM -148.7m)
FCF Yield = -2.25% (FCF TTM -148.7m / Enterprise Value 6.60b)
FCF Margin = -6.94% (FCF TTM -148.7m / Revenue TTM 2.14b)
Net Margin = -0.66% (Net Income TTM -14.2m / Revenue TTM 2.14b)
Gross Margin = 9.38% ((Revenue TTM 2.14b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = -2.85% (prev 13.86%)
Tobins Q-Ratio = 1.70 (Enterprise Value 6.60b / Total Assets 3.89b)
Interest Expense / Debt = 2.53% (Interest Expense 70.3m / Debt 2.78b)
Taxrate = 46.58% (14.9m / 31.9m)
NOPAT = 54.1m (EBIT 101.3m * (1 - 46.58%))
Current Ratio = 1.17 (Total Current Assets 740.8m / Total Current Liabilities 635.6m)
Debt / Equity = 2.57 (Debt 2.78b / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 7.21 (Net Debt 2.33b / EBITDA 322.8m)
Debt / FCF = -15.64 (negative FCF - burning cash) (Net Debt 2.33b / FCF TTM -148.7m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.39% (Net Income -14.2m / Total Assets 3.89b)
RoE = -1.21% (Net Income TTM -14.2m / Total Stockholder Equity 1.17b)
RoCE = 4.55% (EBIT 101.3m / Capital Employed (Equity 1.17b + L.T.Debt 1.06b))
RoIC = 1.65% (NOPAT 54.1m / Invested Capital 3.27b)
WACC = 6.92% (E(4.28b)/V(7.06b) * Re(10.55%) + D(2.78b)/V(7.06b) * Rd(2.53%) * (1-Tc(0.47)))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.83 | Cagr: 7.82%
[DCF] Fair Price = unknown (Cash Flow -148.7m)
EPS Correlation: -51.44 | EPS CAGR: -23.22% | SUE: -1.01 | # QB: -1
Revenue Correlation: 99.75 | Revenue CAGR: 12.47% | SUE: 1.95 | # QB: 8
EPS current Quarter (2026-06-30): EPS=0.20 | Chg30d=-8.20% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.26 | Chg30d=+2.70% | Revisions=+43% | Analysts=6
EPS current Year (2026-12-31): EPS=0.52 | Chg30d=-17.71% | Revisions=+0% | GrowthEPS=+32.2% | GrowthRev=+21.9%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=-8.12% | Revisions=+14% | GrowthEPS=+82.9% | GrowthRev=+10.3%
[Analyst] Revisions Ratio: +43%